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Objectives. We examined whether plasma brain natriuretic 
peptide levels are abnormally elevated inhypertrophic obstructive 
cardiomyopathy compared with other cardiac diseases. 
Background. We previously reported that plasma brain and 
atrial natriuretic peptide levels were elevated in hypertrophic 
cardiomyopathy. 
Methods. We compared plasma concentrations of brain and 
atrial natriuretic peptide and hemodynamic and echocardio- 
graphic data in 50 patients with hypertrophic obstructive car- 
diomyopathy (n = 15, mean [-+SD] intraventricular pressure 
gradient 37 -+ 16 mm Hg), hypertrophic nonobstructive cardio- 
myopathy (n = 15), aortic stenosis (n = 10, mean pressure 
gradient 41 -+ 18 mm Hg) and hypertensive h art disease (n = 10, 
mean systolic/diastolic blood pressure 203 -+ 16/108 -+ 11 mm Hg, 
respectively) and 10 normal subjects. 
Results. Plasma brain natriuretic peptide levels were higher in 
the hypertrophic obstructive cardiomyopathy group (397.1 -+ 
167.8 pg/ml*) than in the hypertrophic nonobstructive cardiomy- 
opathy (60.0 -+ 48.1 pg/ml*t), hypertensive h art disease (53.9 + 
31.4 pg/ml*?), aortic stenosis (75.4 -+ 54.3 pg/ml*t) and normal 
groups (9.8 -+ 6.4 pg/mlt [*p < 0.05 vs. normal group, tP < 0.05 
vs. hypertrophic obstructive cardiomyopathy group]). Although 
plasma trial natriuretic peptide levels were higher in the hyper- 
trophic obstructive cardiomyopathy group than the other patient 
groups, the brain/atrial natriuretic peptide ratio in the hypertro- 
phic obstructive cardiomyopathy group was higher (4.5 -+ 2.3) 
than those in the other three patient groups (1.1 to 1.4) and the 
normal group (0.7 -+ 0.5). Left ventricular end-diastolic pressure 
and left ventricular end-diastolic volume index were similar 
among the four patient groups. The interventricular septal thick- 
ness and the ratio of interventricular septal thickness to left 
ventricular posterior wall thickness were similar between the 
hypertrophic obstructive and nonobstructive cardiomyopathy 
groups. 
Conclusions. Abnormal elevations of plasma brain natriuretic 
peptide levels are di~icult to explain on the basis of hemodynamic 
and echocardiographic data and are a special feature of hyper- 
trophic obstructive cardiomyopathy. 
(J Am Coil Cardiol 1996;28:1234-42) 
Hypertrophic cardiomyopathy is acardiac disease of unknown 
origin that has inappropriate (i.e., unrelated to any pressure or 
volume overload) myocardial hypertrophy, predominantly in-
volving the interventricular septum of a nondilated left ven- 
tricle, with ventricular hyperdynamic systolic function and 
ventricular diastolic dysfunction. In some patients with hyper- 
trophic cardiomyopathy, an intraventricular dynamic pressure 
gradient is observed that divides the left ventricle into a high 
pressure apical region and a low pressure subaortic region. 
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These patients have been classified as having hypertrophic 
obstructive cardiomyopathy, which accounts for only 7% to 
30% of hypertrophic cardiomyopathy cases in the Japanese 
population (1); but 80% to 90% of those in European and 
American populations (2). The transformation f obstructive 
into nonobstructive or of nonobstructive into obstructive is 
observed in only 5% of patients with hypertrophic cardiomy- 
opathy (3). 
Brain natriuretic peptide, originally isolated from the mam- 
malian brain (4), is a novel natriuretic peptide with striking 
structural and biologic similarities to atrial natriuretic peptide 
(5). Brain natriuretic peptide has been recently found in 
human cardiac tissue and plasma (6,7). In the human heart, 
brain natriuretic peptide is synthesized primarily by the ven- 
tricles (8), and its expression in the ventricles is greatly 
accelerated in ventricular overload and hypertrophy, causing 
congestive heart failure (5,8-10). However, we previously 
reported (11) that plasma atrial and brain natriuretic peptide 
levels are elevated in patients with hypertrophic cardiomyop- 
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athy with normal systolic function as well as in those with 
congestive heart failure. In ventricular myocytes of tissue 
obtained from endomyocardial biopsy, positive atrial natri- 
uretic peptide immunoreactivity was found both in patients 
with hypertrophic obstructive cardiomyopathy and in those 
with hypertrophic nonobstructive cardiomyopathy (12), but 
positive brain natriuretic peptide immunoreactivity was seen 
only in patients with hypertrophic obstructive cardiomyopathy 
(11). These findings suggest hat the presence of the obstruc- 
tion in hypertrophic cardiomyopathy may contribute to the 
accelerated synthesis and secretion of ventricular brain natri- 
uretic peptide. However, it is unknown whether any difference 
in plasma levels of brain natriuretic peptide between hypertro- 
phic obstructive and hypertrophic nonobstructive cardiomyop- 
athy is present. Also, the correlations between plasma brain 
natriuretic peptide levels and hemodynamic or echocardio- 
graphic data has not been studied in patients with hypertrophic 
obstructive cardiomyopathy. 
Therefore, the present study was designed to assess 1) 
whether plasma concentrations of brain natriuretic peptide in 
hypertrophic obstructive cardiomyopathy are higher than those 
in hypertrophic nonobstructive cardiomyopathy, aortic stenosis 
as a representative disease of left ventricular high pressure and 
hypertensive heart disease with concentric hypertrophy of the 
left ventricle due to pressure overload; and 2) whether abnor- 
mal elevation of plasma brain natriuretic peptide levels in 
hypertrophic obstructive cardiomyopathy is related to hemo- 
dynamic or echocardiographic data. 
Methods  
Subjects. The study included 50 patients with hypertrophic 
obstructive cardiomyopathy (n -- 15), hypertrophic nonob- 
structive cardiomyopathy (n = 15), aortic stenosis (n = 10) and 
hypertensive heart disease (n = 10) who were evaluated 
clinically by both cardiac catheterization and echocardiography 
(Table 1). The mean ages of the patients with aortic stenosis 
and hypertensive heart disease were matched with those of 
patients with hypertrophic obstructive and nonobstructive car- 
diomyopathy. All patients had normal sinus rhythm without 
critical ectopic premature contractions as evaluated by 24-h 
Holter electrocardiographic (ECG) monitoring and coronary 
arteries without significant stenosis and normal left ventricular 
ejection fraction at cardiac catheterization• Except for those 
with aortic stenosis, the patients had no evidence of critical 
aortic or mitral regurgitation or stenosis by both cardiac 
catheterization and echocardiography. The patients with aortic 
stenosis had no critical mitral regurgitation or stenosis. All 
patients were in New York Heart Association functional class 
I or II (mainly first degree for each patient group). There were 
no differences in degree among the four patient groups. There 
were no significant differences in drugs used between the 
hypertrophic obstructive and nonobstructive cardiomyopathy 
groups. 
The diagnosis of hypertrophic cardiomyopathy was made 
according to the definition and classification proposed by the 
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World Health Organization/International Society and Federa- 
tion of Cardiology Task Force (13). Thirty patients with 
hypertrophic cardiomyopathy ad asymmetric ventricular sep- 
tal hypertrophy evaluated by two-dimensional echocardiogra- 
phy and biventriculography performed uring cardiac cathe- 
terization. In the present study, the patients with hypertrophic 
cardiomyopathy with a left intraventricular p essure gradient 
>16 mm Hg were classified as having hypertrophic obstructive 
cardiomyopathy (14). Fifteen of the patients with hypertrophic 
cardiomyopathy ad a significant systolic intraventricular p es- 
sure gradient >16 mm Hg at rest or after provocation by amyl 
nitrite and revealed intraventricular cceleration flow images 
from the site of stenosis to the left ventricular outflow tract 
during systole in color images on Doppler echocardiography 
(15). The minimal and maximal intraventricular p essure gra- 
dients in patients with hypertrophic obstructive cardiomyopa- 
thy were 18 and 70 mm Hg, respectively. The other 15 patients 
with hypertrophic cardiomyopathy showed no sign of an intra- 
ventricular pressure gradient (within physiologic range) by 
either cardiac catheterization r echocardiography; they were 
classified as having hypertrophic nonobstructive cardiomyo- 
pathy. 
In patients with hypertrophic obstructive cardiomyopathy, 
the diagnosis of both midventricular nd subaortic obstruction 
was made on the basis of typical angiographic and echocardio- 
graphic features: The former is characterized by an hourglass 
appearance of the left ventricle with midventricular obstruc- 
tion and an apical chamber (3 of 15 cases), whereas the latter 
is characterized by an obstruction at the site of the left 
ventricular outflow tract (12 of 15 cases) (16). 
Ten patients with hypertensive heart disease had high 
systemic systolic (maximal) blood pressure and diastolic (min- 
imal) blood pressure at rest (significantly >180 and 90 mm Hg, 
respectively) despite medication for hypertension for at least 2 
years. The mean systolic and diastolic blood pressures were 
203 _+ 16 and 108 _+ 11 mm Hg, respectively (Table 1). All 
patients with hypertensive heart disease had left ventricular 
concentric hypertrophy on two-dimensional echocardiography 
and left ventriculography during cardiac catheterization. The 
mean interventricular septal and left ventricular posterior wall 
thicknesses among patients with hypertensive h art disease are 
shown in Table 1. 
In 10 patients with aortic stenosis, the minimal and maximal 
pressure gradients through the aortic valve were 20 and 
75 mm Hg, respectively (Table 1). 
The control group included 10 normal patients with clini- 
cally suspected cardiac disease because of atypical chest pain 
or minimal ECG changes but no specific or critical abnormal- 
ities on echocardiography and cardiac catheterization. Their 
mean ages matched those of the other patient groups. All 
normal control subjects received no medication. 
All subjects gave written informed consent to participate in 
the study, which was approved by the local ethics committee on 
human research (Gifu University). 
Plasma sampling. Drugs were stopped, and patients fasted 
overnight, After a 19-gauge butterfly needle connected to a 
three-way stopcock was inserted into the antecubital vein, all 
subjects assumed a supine position with eyes closed for at least 
30 min before blood sampling. Peripheral venous blood sam- 
ples were taken slowly through the three-way stopcock and 
transferred to chilled disposable tubes containing 2-natrium- 
ethylenediaminetetraacetic acid (1.5 mg/ml) and aprotinin 
(50/xl/ml) for brain and atrial natriuretic peptide assay. The 
blood samples were placed immediately on ice and promptly 
centrifuged at 4°C, and aliquots of plasma were immediately 
stored at -80°C until the assay. 
In eight hypertrophic obstructive cardiomyopathy and five 
hypertrophic nonobstructive cardiomyopathy group patients, 
second plasma sampling to measure reproducibility of plasma 
atrial and brain natriuretic peptide levels was performed 2
weeks after the first plasma sampling. 
Measurement of brain and atrial natriuretic peptide 
plasma levels. Plasma brain natriuretic peptide concentra- 
tions were measured with a specific immunoradiometric assay 
for human brain natriuretic peptide (17). This assay system 
uses two monoclonal antibodies against alpha-human brain 
natriuretic peptide, one recognizing a carboxy terminal se- 
quence and the other the ring structure of human brain 
natriuretic peptide, and measures human brain natriuretic 
peptide by sandwiching it between the two antibodies without 
extraction of plasma. The minimal detectable quantity of 
human brain natriuretic peptide was 2 pg/ml. The intraassay 
and interassay coefficients of variation were 5.3% and 5.9%, 
respectively, and recovery rates of 10 to 300 pg/ml of human 
brain natriuretic peptide added to plasma were 105.7 _+ 5.4%. 
The correlation between the plasma level of human brain 
natriuretic peptide measured by this method and that by the 
extraction method was highly significant (range 0 to 
1,500 pg/ml, r = 0.98, p < 0.001). The cross-reactivity for 
alpha-human atrial natriuretic peptide was <0.001% on a 
molar basis. 
Plasma atrial natriuretic peptide concentrations were mea- 
sured with a specific immunoradiometric assay for alpha- 
human atrial natriuretic peptide (Shionoria ANP kit, Shionogi, 
Japan), as reported previously by Hama et al. (18). This assay 
is performed in the same manner as that for brain natriuretic 
peptide. The minimal detectable quantity of alpha-human 
atrial natriuretic peptide was 5 pg/ml. The intraassay and 
interassay coefficients of variation were 4.7% and 5.8%, re- 
spectively, and recovery rates of 20 to 600 pg/ml of alpha- 
human atrial natriuretic peptide added to plasma were 99.2 _-2- 
3.0%. The correlation between the plasma level of alpha- 
human atrial natriuretic peptide measured by this method and 
that by the extraction method was highly significant (range 
20 to 1,500 pg/ml, r = 0.97, p < 0.001). The cross-reactivity 
with human brain natriuretic peptide was <0.001% on a molar 
basis. 
Cardiac catheterization. Cardiac catheterization was per- 
formed within 2 weeks before or after blood sampling. All 
patients and normal control subjects underwent both right and 
left heart catheterization according to standard techniques. 
During measurement of intraventricular pressures in pa- 
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tients with hypertrophic obstructive cardiomyopathy, care was 
taken to exclude the possibility of a pressure difference being 
artifactually produced by entrapment of the left ventricular 
catheter in areas of the ventricle that became obliterated 
during systole. Criteria used to exclude the possibility of 
catheter entrapment included verification that the catheter tip 
was freely mobile in a blood-filled area of the left ventricular 
cavity (i.e., blood could be withdrawn from the catheter 
throughout he cardiac cycle), and left ventricular systolic 
pressure was not prolonged (i.e., it declined at or before the 
dicrotic notch of the systemic arterial pressure contour) (3). 
Echocardiography. Echocardiography (HP 77020AC, 
Hewlett-Packard Co.) was performed twice at intervals of >1 
week (mean interval 22 ± 18 days, range 7 to 60) for 
comparison of pressure gradients, which was done by a single 
operator (M.T.) according to established methodology. The 
first echocardiographic study was performed within 1 week 
before or after blood sampling. Interventricular septal thick- 
ness, left ventricular posterior wall thickness, left ventricular 
end-diastolic dimension, intraventricular flow velocity in pa- 
tients with hypertrophic obstructive cardiomyopathy, and aor- 
tic flow velocity in those with aortic stenosis, were measured 
according to standard procedures. Interventricular septal 
thickness was measured at the mitral leaflet tips as the 
reference standard. However, thickness at the midventricular 
level was used for patients with midventricular obstruction 
because maximal septal thickness is usually at the midventricu- 
lar level. The pressure gradient was measured using the 
modified Bernoulli equation (AP = 4V 2, where AP -- pressure 
gradient; and V = peak velocity) from continuous wave 
Doppler echocardiograms (19). 
Statistical analysis. Plasma levels of brain and atrial natri- 
uretic peptide and hemodynamic and echocardiographic vari- 
ables were compared among the patient groups and the control 
group using one-way analysis of variance, and if significant, a 
modified unpaired t test was performed to assess which group 
was significantly different. Correlations of plasma levels of 
brain and atrial natriuretic peptide with hemodynamic and 
echocardiographic variables were examined using simple linear 
regression analysis by the least-squares method, and differ- 
ences between regression lines were tested by analysis of 
covariance using brain or atrial natriuretic peptide as a depen- 
dent variable and a hemodynamic or echocardiographic vari- 
able as an independent variable. Results are expressed as mean 
value ± SD. Statistical significance was defined as p < 0.05. 
Resu l ts  
Patient characteristics. Table 1 shows the clinical profiles 
and cardiac catheterization data for the patient groups and 
control subjects. There were no significant differences in age or 
gender among the five groups. Left ventricular end-diastolic 
and pulmonary artery wedge pressures were similar among 
hypertrophic obstructive cardiomyopathy, hypertrophic non- 
obstructive cardiomyopathy, and aortic stenosis groups. Pul- 
monary artery pressure was similar between hypertrophic 
obstructive and nonobstructive cardiomyopathy groups. Car- 
diac index and heart rate showed no significant difference 
among patient groups and normal subjects. 
The left intraventricular p essure gradient in patients with 
hypertrophic obstructive cardiomyopathy was similar to that 
through the aortic valve in patients with aortic stenosis. The 
difference between initial and second left intraventricular 
pressure gradients measured -3  weeks after the first echocar- 
diographic study in the hypertrophic obstructive cardiomyop- 
athy group was very small (5.6 ± 2.3%). The first and second 
left intraventricular pressure gradients in the hypertrophic 
nonobstructive cardiomyopathy group were within the physio- 
logic range in all patients. Interventricular septal thickness and 
the interventricular septal/left ventricular posterior wall thick- 
ness ratio were not significantly different between the hyper- 
trophic obstructive and nonobstructive cardiomyopathy groups 
(Table 1). There was no significant difference in left ventricular 
end-diastolic volume index among the five patient groups 
(Table 1). 
Plasma concentrations of natriuretic peptides. Plasma lev- 
els of brain natriuretic peptide were 397.1 ± 167.8 pg/ml for 
hypertrophic obstructive cardiomyopathy, 60.0 _ 48.1 pg/ml 
for hypertrophic nonobstructive cardiomyopathy, 53.9 ± 
31.4 pg/m! for hypertensive h art disease, 75.4 ± 54.3 pg/ml for 
aortic stenosis and 9.8 ± 6.4 pg/ml for normal subjects (Fig. 1). 
Plasma concentrations of brain natriuretic peptide in all pa- 
tient groups were significantly higher than those in normal 
subjects. Moreover, brain natriuretic peptide levels in patients 
with hypertrophic obstructive cardiomyopathy were markedly 
higher than those in the other patient groups and in normal 
subjects (-6-fold relative to the other patient groups, 40-fold 
relative to normal subjects). In contrast, plasma concentrations 
of atrial natriuretic peptide (hypertrophic obstructive cardio- 
myopathy: 99.6 ± 41.6 pg/ml; hypertrophic nonobstructive 
cardiomyopathy: 48.6 ± 24.2 pg/ml; hypertensive h art disease: 
47.2 ± 22.4 pg/ml; aortic stenosis: 60.5 ± 26.6 pg/ml) were also 
higher in all patient groups than in normal subjects (17.3 ± 
8.0 pg/ml); those in patients with hypertrophic obstructive 
cardiomyopathy were six times higher than those in normal 
subjects. The plasma concentration ratio of brain to atrial 
natriuretic peptide in patients with hypertrophic obstructive 
cardiomyopathy (4.5 ± 2.3) was significantly higher than that 
in the other patient groups (hypertrophic nonobstructive car- 
diomyopathy: 1.4 ± 1.1; hypertensive heart disease: 1.1 ± 0.3; 
aortic stenosis: 1.4 ± 1.2) and in normal subjects (0.7 ± 0.5). 
The sensitivity and specificity of hypertrophic obstructive car- 
diomyopathy for plasma brain natriuretic peptide levels 
>200 pg/ml were 86.7% and 93.3%, respectively, and 80.0% 
and 73.3%, respectively, for the plasma brain/atrial natriuretic 
peptide ratio >2.5. The reproducibilities ofboth plasma brain 
and atrial natriuretic peptide levels at intervals of 2 weeks were 
<6.8% and 4.7%, respectively. 
Correlation between plasma natriuretic peptides and echo- 
cardiographic and hemodynamic variables. Plasma atrial na- 
triuretic peptide levels were not correlated with any echocar- 
diographic or hemodynamic variables hown in Table 1 in all 
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Figure 1. Comparisons of plasma concentrations f brain natriuretic 
peptide (BNP) and atrial natriuretic peptide (ANP) and plasma 
brain/atrial natriuretic peptide ratios in patients groups and normal 
control subjects. AS = aortic stenosis; HHD = hypertensive h art 
disease; HNCM - hypertrophic nonobstructive cardiomyopathy; 
HOCM : hypertrophic obstructive cardiomyopathy. In the hypertro- 
phic obstructive cardiomyopathy group, solid circles = rest left 
ventricular outflow tract obstruction; open circles = provoked left 
ventricular outflow tract obstruction; circles with solid centers = rest 
midventricular obstruction cases; circles with open centers = provoked 
midventricular obstruction. *p < 0.05 versus normal subjects. #p < 
0.05 versus hypertrophic obstructive cardiomyopathy. Results are 
mean value _+ SD. 
patient groups. Plasma brain natriuretic peptide levels were 
significantly correlated with left ventricular end-diastolic pres- 
sure in aortic stenosis but not in hypertrophic obstructive 
cardiomyopathy, pertrophic nonobstructive cardiomyopathy 
and hypertensive heart disease. Plasma brain natriuretic pep- 
tide levels were significantly correlated with pressure gradient 
through the aortic valve in aortic stenosis (r = 0.631, p < 0.05) 
but not with the intraventricular pressure gradient at the 
obstructed site in hypertrophic obstructive cardiomyopathy 
(Fig. 2). Plasma brain natriuretic peptide levels were signifi- 
cantly correlated with interventricular septal thickness and 
interventricular septal thickness/left ventricular posterior wall 
thickness ratios in hypertrophic obstructive cardiomyopathy, 
hypertrophic nonobstructive cardiomyopathy and hypertensive 
heart disease but not aortic stenosis (Fig. 3). There were no 
significant correlations between plasma brain natriuretic pep- 
tide levels and other hemodynamic or echocardiographic vari- 
ables shown in Table 1 for each of the five groups. 
Discuss ion  
Definition of hypertrophic obstructive cardiomyopathy and 
reproducibility of pressure gradients and plasma natriuretic 
peptide levels. On Doppler echocardiography, significant sys- 
tolic pressure gradient indicating obstruction is >16 mm Hg 
(flow velocity >2 m/s; Pressure gradients = 4 × (Flow 
velocity) 2mm Hg [simplified Bernoulli equation]) with intra- 
ventricular acceleration flow images at a site from the stenotic 
region to the ventricular outflow tract during systole in color 
images (14,15). At cardiac catheterization, significant systolic 
left intraventricular pressure gradient was >20 mm Hg, al- 
though the cut point of significant pressure gradient depends 
on the investigators. In addition, the diagnoses of both mid- 
ventricular and subaortic obstructions were made on the basis 
of typical left ventriculographic and echocardiographic fea- 
tures: The former is characterized by an hourglass appearance 
of the left ventricle with midventricular obstruction and an 
apical chamber, whereas the latter is characterized by the 
obstruction at the site of the left ventricular outflow tract (16). 
In the present study, systolic intraventricular p essure gra- 
dient in hypertrophic nonobstructive cardiomyopathy was zero 
in all 15 patients by cardiac catheterization. On Doppler 
echocardiography, the flow velocity was 0.6 to 1.4 m/s (when 
flow velocity was <2 m/s, calculation of mm Hg by simplified 
Bernoulli equation was not used generally). There was no 
evidence of intraventricular acceleration flow images or mor- 
phologic findings of obstruction i any patient. 
In contrast, all 15 patients with hypertrophic obstructive 
cardiomyopathy had a systolic intraventricular pressure gradi- 
ent of 18 to 70 mm Hg by Doppler echocardiography and 21 to 
73 mm Hg by cardiac catheterization. I  all 15 patients, 
intraventricular cceleration flow images were seen at the site 
of the stenotic region extending to the left ventricular outflow 
tract during systole in color images on Doppler echocardiog- 
raphy. In addition, typical morphologic features of obstruction 
were observed by echocardiography and left ventriculography. 
Therefore, our definition of hypertrophic obstructive and 
nonobstructive cardiomyopathy is similar to that used gener- 
ally. 
It has been established that there are precise positive 
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correlations between the Doppler-determined pressure gradi- 
ent and the simultaneously measured catheter pressure gradi- 
ent both in patients with aortic stenosis and in those with 
hypertrophic obstructive cardiomyopathy (15,20). This corre- 
lation was confirmed by the present data on pressure gradients 
between Doppler echocardiography and cardiac catheteriza- 
tion (r = 0.93, p < 0.05 in hypertrophic obstructive cardiomy- 
opathy; r = 0.96, p < 0.05 in aortic stenosis). The present study 
used Doppler echocardiography to show that the variability of 
pressure gradients at mean intervals of 3 weeks was very small 
in the hypertrophic obstructive and nonobstructive cardiomy- 
opathy groups. Brain and atrial natriuretic peptide plasma 
levels at intervals of 2 weeks were similar in the hypertrophic 
obstructive cardiomyopathy and hypertrophic nonobstructive 
cardiomyopathy groups. These findings indicate that pressure 
gradients and plasma natriuretic peptide levels were stable in 
hypertrophic cardiomyopathy. 
Brain natriuretic peptide plasma levels and plasma brain/ 
atrial natriuretic peptide ratios in hypertrophic obstructive 
cardiomyopathy versus other cardiac diseases. The present 
study revealed marked increases in plasma brain natriuretic 
peptide levels and the plasma brain/atrial natriuretic pcptide 
ratio in hypertrophic obstructive cardiomyopathy. Our findings 
regarding hypertrophic nonobstructive cardiomyopathy, hyper- 
tensive heart disease and aortic stenosis confirmed those of 
previous reports (11,21,22). Hypertrophic nonobstructive and 
obstructive cardiomyopathy showed a similar interventricular 
septal thickness, left ventricular posterior wall thickness, inter- 
Figure 2. Correlation of left intraventricular pressure gradient in 
patients with hypertrophic obstructive cardiomyopathy (left) or pres- 
sure gradient through the aortic valve in patients with aortic stenosis 
(right) and plasma concentrations of brain (BNP) and atrial natriuretic 
peptide (ANP). Symbols as in Figure 1. 
ventricular septal thickness/left ventricular posterior wall 
thickness ratio, left ventricular end-diastolic pressure and left 
ventricular end-diastolic volume index. The hypertensive h art 
disease group had left ventricular concentric hypertrophy 
resulting from a severe, continuous pressure overload, and the 
aortic stenosis group had pressure gradient similar to the 
hypertrophic obstructive cardiomyopathy group. However, 
plasma brain natriuretic peptide levels and the plasma brain/ 
atrial natriuretic peptide ratio in hypertrophic obstructive 
cardiomyopathy were clearly higher than in the other diseases, 
indicating that an increase in brain natriuretic peptide levels in 
hypertrophic obstructive cardiomyopathy cannot be explained 
by cardiac hypertrophy, asymmetric septal hypertrophy or 
pressure overload. 
Most patients with hypertrophic obstructive cardiomyopa- 
thy were in functional class I. In patients with congestive heart 
failure, plasma brain natriuretic peptide increases in relation to 
functional class or left ventricular end-diastolic pressure and 
becomes marked in severe congestive heart failure (functional 
class IV). However, the plasma brain/atrial natriuretic peptide 
ratio was -1.7, even for function class IV. This ratio was 
clearly low compared with that for hypertrophic obstructive 
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Figure 3. Correlation of plasma concentrations 
of brain natriuretic peptide (BNP) and inter- 
ventricular septal thickness (IVSth) (upper 
panels) and between plasma brain natriuretic 
peptide and the interventricular septal thick- 
ness/left ventricular wall thickness ratio (IVSth/ 
LVPWth) (lower panels) in four patient groups 
and normal subjects. Other abbreviations and 
symbols as in Figure 1. 
cardiomyopathy (4.5 + 2.3) in the present study. In contrast, it
has been reported (23) that plasma brain natriuretic peptide 
levels and the plasma brain/atrial natriuretic peptide ratio are 
elevated markedly in the acute stage of myocardial infarction. 
Our findings in the hypertrophic obstructive cardiomyopathy 
group are similar to those in the acute stage of myocardial 
infarction, although ypertrophic obstructive cardiomyopathy 
is not an acute necrotic disease. 
Correlation between elevation of plasma brain natriuretic 
peptide levels and hemodynamic or echocardiographic data in 
hypertrophic obstructive cardiomyopathy. The present study 
showed that plasma brain natriuretic peptide levels in hyper- 
trophic obstructive cardiomyopathy were not correlated with 
any hemodynamic variables, such as pressure gradient or left 
ventricular end-diastolic pressure. However, the degree of 
pressure gradient may change in hypertrophic obstructive 
cardiomyopathy, and changes in the pressure gradient may be 
related to plasma brain natriuretic peptide levels. We cannot 
exclude this possibility. However, the difference in pressure 
gradient over a period of -3  weeks was very small. 
Elevation of plasma brain natriuretic peptide levels corre- 
lated positively with interventricular septal thickness and the 
interventricular septal thickness/left ventricular posterior wall 
thickness ratio in both hypertrophic obstructive and nonob- 
structive cardiomyopathy. This finding indicates the impor- 
tance of ventricular septal mass in the expression of plasma 
brain natriuretic peptide in hypertrophic obstructive cardiomy- 
opathy. At echocardiographic analysis, the hypertrophic ob- 
structive cardiomyopathy group had an interventricular septal 
thickness and interventricular septal thickness/left ventricular 
posterior wall thickness ratio similar to that in the hypertrophic 
nonobstructive cardiomyopathy group. Because plasma brain 
natriuretic peptide levels were higher in the hypertrophic 
obstructive cardiomyopathy than the hypertrophic nonobstruc- 
tive cardiomyopathy group (approximately sixfold), differences 
in the contents of tissues that express brain natriuretic peptide 
in the ventricular septum between hypertrophic obstructive 
and nonobstructive cardiomyopathy should be considered. 
However, there is no evidence of significant differences be- 
tween hypertrophic obstructive and nonobstructive cardiomy- 
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opathy in the size of myocytes, extent of fibrosis or extent of 
disarray, according to findings from endomyocardial biopsy 
and autopsy studies (24,25). 
The sensitivity and specificity of hypertrophic obstructive 
cardiomyopathy for plasma brain natriuretic peptide levels 
>200 pg/ml and of hypertrophic obstructive cardiomyopathy 
for a plasma brain/atrial natriuretic peptide ratio >2.5 were 
high. These findings indicate that 1) plasma brain natriuretic 
peptide levation in hypertrophic obstructive cardiomyopathy 
may be a special feature that can be used to distinguish 
hypertrophic obstructive from hypertrophic nonobstructive 
cardiomyopathy; and 2) it is difficult to explain the abnormal 
elevation of plasma brain natriuretic peptide levels from 
hemodynamic and echocardiographic data. 
Possible mechanism of abnormal elevations of plasma 
brain natriuretic peptide levels in hypertrophic obstructive 
cardiomyopathy. The first question is whether elevation of 
plasma brain natriuretic peptide levels is due to a decrease in
its excretion or an increase in its production. We previously 
reported (11) that the expression of brain natriuretic peptide in 
ventricular myocytes was not seen in hypertrophic nonobstruc- 
tive cardiomyopathy but was seen in hypertrophic obstructive 
cardiomyopathy. This finding indicates an increase in the 
production of brain natriuretic peptide in the ventricular 
myocytes in hypertrophic obstructive cardiomyopathy. The 
second question is, what is the stimulus for release of brain 
natriuretic peptide? Generally, myocyte stretching has been 
recognized as an important stimulus for release of both atrial 
and brain natriuretic peptide (26). Atrial or ventricular stretch- 
ing is a strong inducer of increases in brain rather than atrial 
natriuretic peptide gene expression, suggesting differential 
regulation of atrial and brain natriuretic peptide. However, 
myocyte stretching is not considered to be important for the 
abnormal increase of plasma brain natriuretic peptide in 
hypertrophic obstructive cardiomyopathy versus hypertrophic 
nonobstructive cardiomyopathy, hypertensive heart disease 
and aortic stenosis because it is difficult to explain the marked 
elevation of plasma brain natriuretic peptide levels from 
hemodynamic and echocardiographic data, as discussed earlier 
in this report. Recently, the gradual disappearance of natri- 
uretic peptide receptor-C transcripts was reported (27) in rat 
cardiac hypertrophy accompanied byincreased atrial and brain 
natriuretic peptide mRNA levels, indicating the presence of a 
downregulation f natriuretic peptide receptor after increases 
in plasma trial and brain natriuretic peptide levels. However, 
whether this downregulation ccurs in humans with hypertro- 
phic obstructive cardiomyopathy is unknown. These findings 
suggest differences in brain natriuretic peptide levels at the 
level of gene expression between patients with hypertrophic 
obstructive and those with nonobstructive cardiomyopathy or 
other cardiac hypertrophy, although ypertrophic obstructive 
and nonobstructive cardiomyopathy ave been grouped to- 
gether because of their similar pathogenic mechanisms. Fur- 
ther investigations are warranted. 
Conclusions. The abnormal elevation of brain natriuretic 
peptide levels and brain/atrial natriuretic peptide ratio, which 
cannot be explained by hemodynamic or echocardiographic 
findings, is a special feature in hypertrophic obstructive car- 
diomyopathy at rest. This elevation of brain natriuretic peptide 
levels may play an important role in the pathophysiology of 
hypertrophic obstructive cardiomyopathy. 
We thank Daniel Mrozek for reading the manuscript of this report. 
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